Elevation of gangliosides in four brain regions from Parkinson’s disease patients with a GBA mutation

Abstract A number of genetic risk factors have been identified over the past decade for Parkinson’s Disease (PD), with variants in GBA prominent among them. GBA encodes the lysosomal enzyme that degrades the glycosphingolipid, glucosylceramide (GlcCer), with the activity of this enzyme defective in...

Full description

Bibliographic Details
Published in:npj Parkinson's Disease
Main Authors: Shani Blumenreich, Tamar Nehushtan, Or B. Barav, Jennifer T. Saville, Tamir Dingjan, John Hardy, Maria Fuller, Anthony H. Futerman
Format: Article
Language:English
Published: Nature Portfolio 2022-08-01
Online Access:https://doi.org/10.1038/s41531-022-00363-2
_version_ 1850392679351844864
author Shani Blumenreich
Tamar Nehushtan
Or B. Barav
Jennifer T. Saville
Tamir Dingjan
John Hardy
Maria Fuller
Anthony H. Futerman
author_facet Shani Blumenreich
Tamar Nehushtan
Or B. Barav
Jennifer T. Saville
Tamir Dingjan
John Hardy
Maria Fuller
Anthony H. Futerman
author_sort Shani Blumenreich
collection DOAJ
container_title npj Parkinson's Disease
description Abstract A number of genetic risk factors have been identified over the past decade for Parkinson’s Disease (PD), with variants in GBA prominent among them. GBA encodes the lysosomal enzyme that degrades the glycosphingolipid, glucosylceramide (GlcCer), with the activity of this enzyme defective in Gaucher disease. Based on the ill-defined relationship between glycosphingolipid metabolism and PD, we now analyze levels of various lipids by liquid chromatography/electrospray ionization-tandem mass spectrometry in four brain regions from age- and sex-matched patient samples, including idiopathic PD, PD patients with a GBA mutation and compare both to control brains (n = 21 for each group) obtained from individuals who died from a cause unrelated to PD. Of all the glycerolipids, sterols, and (glyco)sphingolipids (251 lipids in total), the only lipid class which showed significant differences were the gangliosides (sialic acid-containing complex glycosphingolipids), which were elevated in 3 of the 4 PD-GBA brain regions. There was no clear correlation between levels of individual gangliosides and the genetic variant in Gaucher disease [9 samples of severe (neuronopathic), 4 samples of mild (non-neuronopathic) GBA variants, and 8 samples with low pathogenicity variants which have a higher risk for development of PD]. Most brain regions, i.e. occipital cortex, cingulate gyrus, and striatum, did not show a statistically significant elevation of GlcCer in PD-GBA. Only one region, the middle temporal gyrus, showed a small, but significant elevation in GlcCer concentration in PD-GBA. We conclude that changes in ganglioside, but not in GlcCer levels, may contribute to the association between PD and GBA mutations.
format Article
id doaj-art-eef8903ef3da4d92af2541024a5a2e06
institution Directory of Open Access Journals
issn 2373-8057
language English
publishDate 2022-08-01
publisher Nature Portfolio
record_format Article
spelling doaj-art-eef8903ef3da4d92af2541024a5a2e062025-08-19T22:53:19ZengNature Portfolionpj Parkinson's Disease2373-80572022-08-018111110.1038/s41531-022-00363-2Elevation of gangliosides in four brain regions from Parkinson’s disease patients with a GBA mutationShani Blumenreich0Tamar Nehushtan1Or B. Barav2Jennifer T. Saville3Tamir Dingjan4John Hardy5Maria Fuller6Anthony H. Futerman7Department of Biomolecular Sciences, Weizmann Institute of ScienceDepartment of Biomolecular Sciences, Weizmann Institute of ScienceDepartment of Biomolecular Sciences, Weizmann Institute of ScienceGenetics and Molecular Pathology, SA Pathology at Women’s and Children’s Hospital and Adelaide Medical School, The University of AdelaideDepartment of Biomolecular Sciences, Weizmann Institute of ScienceDepartment of Neurodegenerative Disease, UCL Dementia Research Institute, University College LondonGenetics and Molecular Pathology, SA Pathology at Women’s and Children’s Hospital and Adelaide Medical School, The University of AdelaideDepartment of Biomolecular Sciences, Weizmann Institute of ScienceAbstract A number of genetic risk factors have been identified over the past decade for Parkinson’s Disease (PD), with variants in GBA prominent among them. GBA encodes the lysosomal enzyme that degrades the glycosphingolipid, glucosylceramide (GlcCer), with the activity of this enzyme defective in Gaucher disease. Based on the ill-defined relationship between glycosphingolipid metabolism and PD, we now analyze levels of various lipids by liquid chromatography/electrospray ionization-tandem mass spectrometry in four brain regions from age- and sex-matched patient samples, including idiopathic PD, PD patients with a GBA mutation and compare both to control brains (n = 21 for each group) obtained from individuals who died from a cause unrelated to PD. Of all the glycerolipids, sterols, and (glyco)sphingolipids (251 lipids in total), the only lipid class which showed significant differences were the gangliosides (sialic acid-containing complex glycosphingolipids), which were elevated in 3 of the 4 PD-GBA brain regions. There was no clear correlation between levels of individual gangliosides and the genetic variant in Gaucher disease [9 samples of severe (neuronopathic), 4 samples of mild (non-neuronopathic) GBA variants, and 8 samples with low pathogenicity variants which have a higher risk for development of PD]. Most brain regions, i.e. occipital cortex, cingulate gyrus, and striatum, did not show a statistically significant elevation of GlcCer in PD-GBA. Only one region, the middle temporal gyrus, showed a small, but significant elevation in GlcCer concentration in PD-GBA. We conclude that changes in ganglioside, but not in GlcCer levels, may contribute to the association between PD and GBA mutations.https://doi.org/10.1038/s41531-022-00363-2
spellingShingle Shani Blumenreich
Tamar Nehushtan
Or B. Barav
Jennifer T. Saville
Tamir Dingjan
John Hardy
Maria Fuller
Anthony H. Futerman
Elevation of gangliosides in four brain regions from Parkinson’s disease patients with a GBA mutation
title Elevation of gangliosides in four brain regions from Parkinson’s disease patients with a GBA mutation
title_full Elevation of gangliosides in four brain regions from Parkinson’s disease patients with a GBA mutation
title_fullStr Elevation of gangliosides in four brain regions from Parkinson’s disease patients with a GBA mutation
title_full_unstemmed Elevation of gangliosides in four brain regions from Parkinson’s disease patients with a GBA mutation
title_short Elevation of gangliosides in four brain regions from Parkinson’s disease patients with a GBA mutation
title_sort elevation of gangliosides in four brain regions from parkinson s disease patients with a gba mutation
url https://doi.org/10.1038/s41531-022-00363-2
work_keys_str_mv AT shaniblumenreich elevationofgangliosidesinfourbrainregionsfromparkinsonsdiseasepatientswithagbamutation
AT tamarnehushtan elevationofgangliosidesinfourbrainregionsfromparkinsonsdiseasepatientswithagbamutation
AT orbbarav elevationofgangliosidesinfourbrainregionsfromparkinsonsdiseasepatientswithagbamutation
AT jennifertsaville elevationofgangliosidesinfourbrainregionsfromparkinsonsdiseasepatientswithagbamutation
AT tamirdingjan elevationofgangliosidesinfourbrainregionsfromparkinsonsdiseasepatientswithagbamutation
AT johnhardy elevationofgangliosidesinfourbrainregionsfromparkinsonsdiseasepatientswithagbamutation
AT mariafuller elevationofgangliosidesinfourbrainregionsfromparkinsonsdiseasepatientswithagbamutation
AT anthonyhfuterman elevationofgangliosidesinfourbrainregionsfromparkinsonsdiseasepatientswithagbamutation